Brave or foolish.
Time will tell.
My main concern is our starting point now should any bad news arrive.
If we were around 1.17 again, a poor P 2b result might drop us 50% to .50-.60.
BUT, we’re already at .50, so unless the market has basically priced-in bad P results already, we’re in for low .20s in fairly short order.
Im prepared for that, as quite frankly i never even considered P all that much when buying CTIX many years ago.
Im here for K, and now more importantly, for an ever-expanding indication for a Brilacidin platform that consistently has PROVEN SOLID.
Ill buy into these dips, as i believe a straight buyout, even with a gutter pps, and limited N trial sizes, that B would fetch at very least 1 billion. ~$6.
Worth the risk IMO.
News 
Market Data 
Discover 
